193 related articles for article (PubMed ID: 38521359)
1. Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing pathways in neurodegenerative disorders and cancer.
Kaushik A; Parashar S; Ambasta RK; Kumar P
Ageing Res Rev; 2024 Apr; 96():102279. PubMed ID: 38521359
[TBL] [Abstract][Full Text] [Related]
2. E3 ligases and DUBs target ferroptosis: A potential therapeutic strategy for neurodegenerative diseases.
Lu L; Jifu C; Xia J; Wang J
Biomed Pharmacother; 2024 Jun; 175():116753. PubMed ID: 38761423
[TBL] [Abstract][Full Text] [Related]
3. Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory.
Cowan AD; Ciulli A
Annu Rev Biochem; 2022 Jun; 91():295-319. PubMed ID: 35320687
[TBL] [Abstract][Full Text] [Related]
4. Expanding PROTACtable genome universe of E3 ligases.
Liu Y; Yang J; Wang T; Luo M; Chen Y; Chen C; Ronai Z; Zhou Y; Ruppin E; Han L
Nat Commun; 2023 Oct; 14(1):6509. PubMed ID: 37845222
[TBL] [Abstract][Full Text] [Related]
5. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy.
Sampson C; Wang Q; Otkur W; Zhao H; Lu Y; Liu X; Piao HL
Clin Transl Med; 2023 Mar; 13(3):e1204. PubMed ID: 36881608
[TBL] [Abstract][Full Text] [Related]
6. A critical discussion on the relationship between E3 ubiquitin ligases, protein degradation, and skeletal muscle wasting: it's not that simple.
Hughes DC; Goodman CA; Baehr LM; Gregorevic P; Bodine SC
Am J Physiol Cell Physiol; 2023 Dec; 325(6):C1567-C1582. PubMed ID: 37955121
[TBL] [Abstract][Full Text] [Related]
7. Targeted modulation of E3 ligases using engineered ubiquitin variants.
LeBlanc N; Mallette E; Zhang W
FEBS J; 2021 Apr; 288(7):2143-2165. PubMed ID: 32867007
[TBL] [Abstract][Full Text] [Related]
8. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
9. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
Liu L; Wong CC; Gong B; Yu J
Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
[TBL] [Abstract][Full Text] [Related]
10. Targeted Degradation of 53BP1 Using Ubiquitin Variant Induced Proximity.
Aminu B; Fux J; Mallette E; Petersen N; Zhang W
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454069
[TBL] [Abstract][Full Text] [Related]
11. E3-ubiquitin ligases and recent progress in osteoimmunology.
Asano Y; Matsumoto Y; Wada J; Rottapel R
Front Immunol; 2023; 14():1120710. PubMed ID: 36911671
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin proteasome system in immune regulation and therapeutics.
Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitination and deubiquitination: Implications on cancer therapy.
Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
[TBL] [Abstract][Full Text] [Related]
14. E3-ligase knock down revealed differential titin degradation by autopagy and the ubiquitin proteasome system.
Müller E; Salcan S; Bongardt S; Barbosa DM; Krüger M; Kötter S
Sci Rep; 2021 Oct; 11(1):21134. PubMed ID: 34702928
[TBL] [Abstract][Full Text] [Related]
15. HECT E3 ubiquitin ligases - emerging insights into their biological roles and disease relevance.
Wang Y; Argiles-Castillo D; Kane EI; Zhou A; Spratt DE
J Cell Sci; 2020 Apr; 133(7):. PubMed ID: 32265230
[TBL] [Abstract][Full Text] [Related]
16. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
Rothweiler EM; Brennan PE; Huber KVM
Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.
Lv M; Hu W; Zhang S; He L; Hu C; Yang S
Cancer Lett; 2022 Jul; 539():215716. PubMed ID: 35500825
[TBL] [Abstract][Full Text] [Related]
18. Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases.
Jeong Y; Oh AR; Jung YH; Gi H; Kim YU; Kim K
Exp Mol Med; 2023 Oct; 55(10):2097-2104. PubMed ID: 37779139
[TBL] [Abstract][Full Text] [Related]
19. NEDD4 E3 ubiquitin ligases: Promising biomarkers and therapeutic targets for cancer.
Tian X; Chen Y; Peng Z; Lin Q; Sun A
Biochem Pharmacol; 2023 Aug; 214():115641. PubMed ID: 37307883
[TBL] [Abstract][Full Text] [Related]
20. The role of NEDD4 related HECT-type E3 ubiquitin ligases in defective autophagy in cancer cells: molecular mechanisms and therapeutic perspectives.
Zhang R; Shi S
Mol Med; 2023 Mar; 29(1):34. PubMed ID: 36918822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
